Novartis Ag (NVS) Receivables - Other (2014 - 2024)

Novartis Ag has disclosed Receivables - Other across 11 years of filings, most recently posting $1.3 billion for Q4 2024.

• In Q4 2024, Receivables - Other rose 6.07% year-over-year to $1.3 billion; the TTM figure through Dec 2024 stood at $1.3 billion (up 6.07% YoY), while the FY2024 annual figure was $1.3 billion, up 6.07% from the prior year.
• Receivables - Other came in at $1.3 billion for Q4 2024 at Novartis Ag, up from $1.3 billion in the prior quarter.
• In the past five years, Receivables - Other ranged from a high of $1.3 billion in Q4 2024 to a low of $793.0 million in Q4 2021.
• Average Receivables - Other over 5 years is $1.1 billion, with a median of $963.0 million recorded in 2020.
• Year-over-year, Receivables - Other dropped 17.65% in 2021 and jumped 30.69% in 2023.
• Over 5 years, Receivables - Other stood at $963.0 million in 2020, then fell by 17.65% to $793.0 million in 2021, then increased by 20.81% to $958.0 million in 2022, then jumped by 30.69% to $1.3 billion in 2023, then rose by 6.07% to $1.3 billion in 2024.
• Per Business Quant data, the three most recent Receivables - Other figures were $1.3 billion in Q4 2024, $1.3 billion in Q4 2023, and $958.0 million in Q4 2022.